{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:57:45Z","timestamp":1765961865843,"version":"3.40.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41409-025-02525-1","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:45:04Z","timestamp":1740159904000},"page":"587-594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical characteristics and outcomes of BCMA-targeted CAR-T cell recipients with COVID-19 during the Omicron wave: a retrospective study"],"prefix":"10.1038","volume":"60","author":[{"given":"Haiqiong","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-1852","authenticated-orcid":false,"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-1621","authenticated-orcid":false,"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"2525_CR1","doi-asserted-by":"publisher","first-page":"m1036","DOI":"10.1136\/bmj.m1036","volume":"368","author":"E Mahase","year":"2020","unstructured":"Mahase E. Covid-19: WHO declares pandemic because of \u201calarming levels\u201d of spread, severity, and inaction. BMJ. 2020;368:m1036.","journal-title":"BMJ"},{"key":"2525_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl J Med. 2020;382:727\u201333.","journal-title":"N. Engl J Med"},{"key":"2525_CR3","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1002\/jmv.27643","volume":"94","author":"D Tian","year":"2022","unstructured":"Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J Med Virol. 2022;94:2376\u201383.","journal-title":"J Med Virol"},{"key":"2525_CR4","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ajpath.2022.01.007","volume":"192","author":"PA Christensen","year":"2022","unstructured":"Christensen PA, Olsen RJ, Long SW, Snehal R, Davis JJ, Ojeda Saavedra M, et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the Omicron variant of severe acute respiratory syndrome coronavirus 2 in Houston, Texas. Am J Pathol. 2022;192:642\u201352.","journal-title":"Am J Pathol"},{"key":"2525_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41586-022-04479-6","volume":"603","author":"KPY Hui","year":"2022","unstructured":"Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature. 2022;603:715\u201320.","journal-title":"Nature"},{"key":"2525_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.988694","volume":"12","author":"H Li","year":"2022","unstructured":"Li H, Zhu X, Yu R, Qian X, Huang Y, Chen X, et al. The effects of vaccination on the disease severity and factors for viral clearance and hospitalization in Omicron-infected patients: A retrospective observational cohort study from recent regional outbreaks in China. Front Cell Infect Microbiol. 2022;12:988694.","journal-title":"Front Cell Infect Microbiol"},{"key":"2525_CR7","doi-asserted-by":"crossref","unstructured":"Liu Y, Rocklov J. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. J Travel Med. 2022;29:taac037.","DOI":"10.1093\/jtm\/taac037"},{"key":"2525_CR8","doi-asserted-by":"publisher","first-page":"n2943","DOI":"10.1136\/bmj.n2943","volume":"375","author":"I Torjesen","year":"2021","unstructured":"Torjesen I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ. 2021;375:n2943.","journal-title":"BMJ"},{"key":"2525_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08280-y","volume":"21","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021;21:606.","journal-title":"BMC Cancer"},{"key":"2525_CR10","doi-asserted-by":"publisher","first-page":"e934","DOI":"10.1016\/S2352-3026(21)00278-7","volume":"8","author":"H Ludwig","year":"2021","unstructured":"Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, et al. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021;8:e934\u2013e46.","journal-title":"Lancet Haematol"},{"key":"2525_CR11","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","volume":"7","author":"F Passamonti","year":"2020","unstructured":"Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737\u201345.","journal-title":"Lancet Haematol"},{"key":"2525_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","volume":"14","author":"L Pagano","year":"2021","unstructured":"Pagano L, Salmanton-Garcia J, Marchesi F, Busca A, Corradini P, Hoenigl M, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14:168.","journal-title":"J Hematol Oncol"},{"key":"2525_CR13","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1007\/s00277-021-04594-w","volume":"100","author":"M Krejci","year":"2021","unstructured":"Krejci M, Pour L, Adam Z, Sandecka V, Stork M, Sevcikova S, et al. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. Ann Hematol. 2021;100:2541\u20136.","journal-title":"Ann Hematol"},{"key":"2525_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1158\/2643-3230.BCD-20-0102","volume":"1","author":"M Hultcrantz","year":"2020","unstructured":"Hultcrantz M, Richter J, Rosenbaum CA, Patel D, Smith EL, Korde N, et al. COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. Blood Cancer Discov. 2020;1:234\u201343.","journal-title":"Blood Cancer Discov"},{"key":"2525_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"WH Zhao","year":"2022","unstructured":"Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022;15:86.","journal-title":"J Hematol Oncol"},{"key":"2525_CR16","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2525_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18:71\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"2525_CR18","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8:e446\u2013e61.","journal-title":"Lancet Haematol"},{"key":"2525_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00469-5","volume":"11","author":"PJ Teoh","year":"2021","unstructured":"Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021;11:84.","journal-title":"Blood Cancer J"},{"key":"2525_CR20","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","volume":"37","author":"E Terpos","year":"2023","unstructured":"Terpos E, Musto P, Engelhardt M, Delforge M, Cook G, Gay F, et al. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2023;37:1175\u201385.","journal-title":"Leukemia"},{"key":"2525_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3322\/caac.21771","volume":"73","author":"RH Parikh","year":"2023","unstructured":"Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA Cancer J Clin. 2023;73:275\u201385.","journal-title":"CA Cancer J Clin"},{"key":"2525_CR22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.clml.2023.03.002","volume":"23","author":"JE Wiedmeier-Nutor","year":"2023","unstructured":"Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, et al. Response to COVID-19 vaccination post-CAR T therapy in patients with non-hodgkin lymphoma and multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23:456\u201362.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2525_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32960-3","volume":"13","author":"Y Hu","year":"2022","unstructured":"Hu Y, Li J, Ni F, Yang Z, Gui X, Bao Z, et al. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nat Commun. 2022;13:5313.","journal-title":"Nat Commun"},{"key":"2525_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395.","journal-title":"Blood"},{"key":"2525_CR25","unstructured":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Bethesda (MD); National Institutes of Health; 2021."},{"key":"2525_CR26","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1038\/s41375-021-01302-5","volume":"35","author":"P Ljungman","year":"2021","unstructured":"Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35:2885\u201394.","journal-title":"Leukemia"},{"key":"2525_CR27","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1182\/bloodadvances.2023010524","volume":"7","author":"JS Little","year":"2023","unstructured":"Little JS, Tandon M, Hong JS, Nadeem O, Sperling AS, Raje N, et al. Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy. Blood Adv. 2023;7:5485\u201395.","journal-title":"Blood Adv"},{"key":"2525_CR28","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","volume":"6","author":"S Kambhampati","year":"2022","unstructured":"Kambhampati S, Sheng Y, Huang CY, Bylsma S, Lo M, Kennedy V, et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2022;6:2045\u201354.","journal-title":"Blood Adv"},{"key":"2525_CR29","doi-asserted-by":"crossref","unstructured":"Cordas Dos Santos DM, Tix T, Shouval R, Gafter-Gvili A, Alberge JB, Cliff ERS, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30:2667\u201378.","DOI":"10.1038\/s41591-024-03084-6"},{"key":"2525_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00901-y","volume":"13","author":"AK Mitra","year":"2023","unstructured":"Mitra AK, Mukherjee UK, Mazumder S, Madhira V, Bergquist T, Shao YR, et al. Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma. Blood Cancer J. 2023;13:180.","journal-title":"Blood Cancer J"},{"key":"2525_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/cas.16001","volume":"115","author":"D Jin","year":"2024","unstructured":"Jin D, He J, Wu W, Han X, Le J, Shu W, et al. Outcomes of COVID-19 in multiple myeloma patients treated with daratumumab. Cancer Sci. 2024;115:237\u201346.","journal-title":"Cancer Sci"},{"key":"2525_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.46234\/ccdcw2023.070","volume":"5","author":"D Fu","year":"2023","unstructured":"Fu D, He G, Li H, Tan H, Ji X, Lin Z, et al. Effectiveness of COVID-19 vaccination against SARS-CoV-2 Omicron variant infection and symptoms - China, December 2022-February 2023. China CDC Wkly. 2023;5:369\u201373.","journal-title":"China CDC Wkly"},{"key":"2525_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13956","volume":"53","author":"JPA Ioannidis","year":"2023","unstructured":"Ioannidis JPA, Zonta F, Levitt M. Estimates of COVID-19 deaths in Mainland China after abandoning zero COVID policy. Eur J Clin Invest. 2023;53:e13956.","journal-title":"Eur J Clin Invest"},{"key":"2525_CR34","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1093\/cid\/ciac571","volume":"76","author":"SRK Malahe","year":"2023","unstructured":"Malahe SRK, Hoek RAS, Dalm V, Broers AEC, den Hoed CM, Manintveld OC, et al. Clinical characteristics and outcomes of immunocompromised patients with coronavirus disease 2019 caused by the Omicron variant: a prospective, observational study. Clin Infect Dis. 2023;76:e172\u2013e8.","journal-title":"Clin Infect Dis"},{"key":"2525_CR35","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-022-01887-z","volume":"28","author":"JA Lewnard","year":"2022","unstructured":"Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1\/BA.1.1 or BA.2 subvariant infection in Southern California. Nat Med. 2022;28:1933\u201343.","journal-title":"Nat Med"},{"key":"2525_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-020-00934-x","volume":"13","author":"B Wang","year":"2020","unstructured":"Wang B, Van Oekelen O, Mouhieddine TH, Del Valle DM, Richter J, Cho HJ, et al. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol. 2020;13:94.","journal-title":"J Hematol Oncol"},{"key":"2525_CR37","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/bjh.17937","volume":"196","author":"S Booth","year":"2022","unstructured":"Booth S, Curley HM, Varnai C, Arnold R, Lee LYW, Campton NA, et al. Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy. Br J Haematol. 2022;196:892\u2013901.","journal-title":"Br J Haematol"},{"key":"2525_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00372-5","volume":"10","author":"J Martinez-Lopez","year":"2020","unstructured":"Martinez-Lopez J, Mateos MV, Encinas C, Sureda A, Hernandez-Rivas JA, Lopez de la Guia A, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020;10:103.","journal-title":"Blood Cancer J"},{"key":"2525_CR39","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1007\/s00277-023-05350-y","volume":"102","author":"Q He","year":"2023","unstructured":"He Q, Dou X, Liu Y, Wen L, Wang F, Peng N, et al. Characteristics and outcomes of COVID-19 in patients with plasma cell dyscrasias during the first Omicron wave in Beijing since December 2022: a retrospective study at a National Clinical Research Center for Hematologic Disease. Ann Hematol. 2023;102:2857\u201364.","journal-title":"Ann Hematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02525-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02525-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02525-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T14:28:14Z","timestamp":1746714494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02525-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2525"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02525-1","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}